P1029: MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF PELABRESIB (CPI-0610) IN COMBINATION WITH RUXOLITINIB VS RUXOLITINIB OR FEDRATINIB MONOTHERAPY IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS

Authors :: V. Gupta
J. Mascarenhas
M. Kremyanskaya
R. K. Rampal
M. Talpaz
J.-J. Kiladjian
A. Vannucchi
S. Verstovsek
G. Colak
D. Dey
C. Harrison
Source :: HemaSphere. 6:919-920
Publication Year :: 2022
Publisher :: Ovid Technologies (Wolters Kluwer Health), 2022.

Full Text Access

Tools